We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Stress-Induced tRNA Fragments Prove Early Predictors of Epileptic Seizures

By LabMedica International staff writers
Posted on 24 Jun 2019
Elevated levels of stress-induced fragments of transfer RNA in the blood may serve as biomarkers that indicate potential for an epileptic seizure hours before the event actually occurs.

A transfer RNA (abbreviated tRNA) is an adaptor molecule composed of ribonucleic acid, typically 76 to 90 nucleotides in length, which serves as the physical link between the mRNA and the amino acid sequence of proteins. More...
tRNA does this by carrying an amino acid to the protein synthetic machinery of a cell (ribosome) as directed by a three-nucleotide sequence (codon) in a molecule of mRNA. As such, tRNAs are a necessary component of translation, the biological synthesis of new proteins in accordance with the genetic code. When cells are stressed, tRNAs are cut into fragments.

Investigators at the Royal College of Surgeons in Ireland (Dublin) and the related biotech company FutureNeuro (Dublin, Ireland) proposed that higher levels of tRNA fragments in the blood might indicate that brain cells were under stress in the build up to a seizure event.

To test this hypothesis, the investigators collected plasma samples during video-EEG monitoring of focal epilepsy patients. Small RNA sequencing identified significant differences in three tRNA fragments (5′GlyGCC, 5′AlaTGC, and 5′GluCTC) between epilepsy patients and control subjects. Levels of these tRNA fragments were higher in pre-seizure than post-seizure samples, suggesting they may serve as biomarkers of seizure risk in epilepsy patients.

The investigators designed PCR-based assays to quantify tRNA fragments in a cohort of pre- and post-seizure plasma samples from focal epilepsy patients and healthy controls. Analysis of the results indicated that tRNA fragments potently distinguished pre- from post-seizure patients. Furthermore, elevated tRNA fragments levels were not detected in patients with psychogenic non-epileptic seizures, and did not result from medication tapering.

"New technologies to remove the unpredictability of uncontrolled seizures for people with epilepsy are a very real possibility," said contributing author Dr. David Henshall, professor of molecular physiology and neuroscience at the Royal College of Surgeons in Ireland. "Building on this research we in FutureNeuro hope to develop a test prototype, similar to a blood sugar monitor that can potentially predict when a seizure might occur."

The tRNA biomarker study was published in the April 30, 2019, online edition of the Journal of Clinical Investigation.

Related Links:
The Royal College of Surgeons in Ireland
FutureNeuro



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Steam Sterilizer
Hi Vac II Line
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.